Cataract

Latest News


CME Content


With a wide array of IOL options available to their foreign colleagues, U.S. ophthalmologists eagerly await the approval and availability of additional lenses.

Planning for the fifth year of “Cataract Surgery: Telling It Like It Is,” set for Thursday, Jan. 15, to Sunday, Jan. 18, is well under way and meeting organizer Robert H. Osher, MD, promises “more faculty, more topics, and a lot more fireworks” for this latest gathering here.

Although infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are a prominent concern for cataract surgeons, leading ophthalmologists discuss the pros and cons of performing universal MRSA screening to guide targeted prophylaxis.

Bausch + Lomb’s next-generation sub-micron gel formulation of loteprednol etabonate has been found to be statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day 8-the primary endpoints in the first phase III, multicenter, double-masked, vehicle-controlled, parallel-group study.

A femtosecond laser can create circular, well-centered capsulotomies to facilitate implantation of capsular tension rings and IOLs without decentration in pediatric patients with Marfan’s syndrome. Tim Schultz, MD, and H. Burkhard Dick, MD, of the University Eye Clinic Bochum, Bochum, Germany, described the case of a 10-year-old boy with Marfan’s syndrome.

The recent agreement between Valeant and Croma-which would provide for the distribution of Croma’s ophthalmology products in Western Europe-is expected to expand Bausch + Lomb’s (B + L) ophthalmic portfolio in the United States.

The European Society of Cataract and Refractive Surgeons (ESCRS) never fails to entice ophthalmology with cutting-edge technology, and the XXXII Congress in London has not disappointed attendees. This year’s congress has displayed a wide range of new technologies from cataract and refractive platforms to diagnostic units to surgical instruments. From all the equipment presented, IOL advances have again captured the attention of attendees.

When consulting with patients who present with decreased vision due to cataracts, ophthalmologists need to remember their role as physicians first, suggest the authors. The primary goal of the office visit is to address the complaint and the solution in entirety before moving into outcomes.

The FDA has approved Omeros’ phenylephrine and kertorolac injection 1%/0.3% (Omidria) for use during cataract surgery or IOL replacement (ILR) to maintain pupil size by preventing intraoperative miosis and to reduce postoperative pain.